• search

Cadila gets DGCI nod for Phase II clinical trials of ZYH1

Written by: Staff

New Delhi, Mar 20 (UNI) Cadila Healthcare Ltd today said it has received permission from Drug Controller General of India to conduct Phase II clinical trials on its new molecular entity ZYH1, after successfully completing Phase I clinical trials.

The Phase II studies would focus on evaluating the efficacy of ZYH1.

ZYH1 is expected to address the issue related to patients suffering from dyslipidemia in both diabetic and non-diabetic condition.

The drug, designed and developed by the company's research wing, Zydus Research Centre, is expected to improve lipid profile, leading to decrease in cardiovascular risk in diabetic patients as well as other diabetes-related complications.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more